NRx Pharmaceuticals

NRx Pharmaceuticals is an agile and professional biopharmaceutical company firmly committed to addressing significant unmet medical needs. NRx Pharmaceuticals is developing ZYESAMI (aviptadil acetate) for COVID-19 and NRX-101, the first oral therapy for treating acute suicidal ideation/behavior (ASIB) in bipolar depression. NRx believes that scientific advancements can turn previously untreatable diseases into treatable ones. Leveraging unique clinical and scientific expertise, NRx Pharmaceuticals collaborates with leading medical experts to bring new medicines and hope to patients suffering from chronic conditions.